Three things to know:
1. CartiHeal has completed enrollment and outcome of interim analysis in an investigational device exemption study of Agili-C, an implant for the treatment of cartilage lesions in joints.
2. Bioventus will provide an additional $5 million to CartiHeal if required to complete the device exemption study.
3. Terms of the deal to acquire CartiHeal were not disclosed.
More articles on biologics:
7D Surgical radiation-free spine surgery system gets European approval
Medtronic to buy Medicrea for 22% above share price: 6 details
2 hospitals with new spine surgery programs
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
